PT  - JOURNAL ARTICLE
AU  - Tsutae, Wataru
AU  - Chaochaisit, Wirawit
AU  - Aoshima, Hideyuki
AU  - Ida, Chiharu
AU  - Miyakawa, Shino
AU  - Sekine, Hiroko
AU  - Sheikh, Afzal
AU  - Baran, Iri Sato
AU  - Furukawa, Toshiharu
AU  - Sekine, Akihiro
TI  - Detecting and isolating false negatives of SARS-CoV-2 primers and probe sets among the Japanese Population: A laboratory testing methodology and study
AID  - 10.1101/2020.10.07.20208264
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.07.20208264
4099  - http://medrxiv.org/content/early/2020/10/09/2020.10.07.20208264.short
4100  - http://medrxiv.org/content/early/2020/10/09/2020.10.07.20208264.full
AB  - The global COVID-19 pandemic has spread across various continents in diverse methods and speed while opening up discussion for technological and scientific questions pertaining methodology of testing accuracy among diverse viral strains.On the issue of testing sensitivity and accuracy, RT-PCR is commonly viewed as a standard testing protocol globally as the predominant accurate testing method vis-à-vis other rapid methods. However, each country’s infectious disease authority has established its own primers/probe sets guidelines and protocols, thereby, the global testing community lacks a “Standardized Universal Primer(s)” (SUP) that is foolproof for the COVID-19 patients among various populations today. As a result, RT-PCR testing accuracy and results may vary depending on which primer was used, most likely resulting in false negative and/or false positive calls associated with RT-PCR testing.In this study, a comparative study between primers from different countries’ disease control centers was conducted. 11,652 samples from Japanese population were tested for SARS-CoV-2 positive using recommended RT-PCR primers/probe sets from Japan National Institute of Infectious Disease (NIID) and US Centers for Disease Control and Prevention (CDC).Results Of the 102 positive samples, 17 samples (16.7% of total positives) showed inconsistent results when tested for the following primers: JPN-N2, JPN-N1, CDC-N1, and CDC-N2. In addition, CDC recommended primer/probe sets showed relatively higher sensitivity and accuracy among the primer/probe sets used for the detection of SARS-CoV-2 positive clones.Conclusion Due to the inconsistency in the positive/negative results for JPN-N2, JPN-N1, CDC-N1, and CDC-N2 primer/probe sets, SARS-CoV-2 samples run via RT-PCR will result in false negative/positive subjected to differences in virus mutation in a specific sequence region targeted by a primer. This outcome shows that the use of JPN-N2 primer combined with CDC-N2 primer produces the most effective result to reduce false negatives in Japan region. Furthermore, adding CDC-N1 will result in reducing false negatives, but also false positives. Further investigation remains open for confirmation whether similar irregular pattern occur with primers targeting other regions such as E or ORF1ab in order to isolate false negatives and/or positives in future PCR testing for COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.niid.go.jp/niid/images/epi/corona/2019-nCoVmanual20200217-en.pdf Funding StatementSelf-funded by Genesis Healthcare Co.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Biological samples were collected from volunteers, self-medication testing participants and patients under physician care administering clinical testing for SARS-CoV-2 (COVID-19). Samples were anonymized and de-identified, so laboratory technicians and researchers were blind to the identity of the patients. Only secondary non-identifying data including age, biological sex and symptoms were provided. All experimental protocols were approved by Genesis Healthcare's Ethics Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used and produced in this research are available at: https://github.com/genesis-healthcare/covid-19_pcr_irregularities　 https://github.com/genesis-healthcare/covid-19_pcr_irregularities